View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Texas Pacific Land Corp: 2 directors

A director at Texas Pacific Land Corp bought 12 shares at 1,376.900USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

Continental Resources, Inc.: Debt reduction bolsters credit profile

Our credit view of this issuer reflects its high operating and capital efficiency, constrained by its elevated level of debt, pending further reduction in 2024.

Moody's announces completion of a periodic review of ratings of Contin...

Moody's Ratings has completed a periodic review of the ratings of Continental Resources, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 14 March 2024 in which Moody's reassessed the appropriateness of the ratings in the conte...

Continental Resources, Inc.: Strong free cash flow generation will sup...

Our credit view of this issuer reflects its high operating and capital efficiency, and high resiliency of its strong free cash flow generation, against high absolute level of debt.

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
Andreas Argyrides ... (+9)
  • Andreas Argyrides
  • Caroline Pocher
  • David Nierengarten
  • Dennis Pak
  • Laura Chico
  • Liana Moussatos
  • Ritika Das
  • Robert Driscoll
  • Sam Ravina
OC OWENS CORNING
BLUE BLUEBIRD BIO INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
SGMO SANGAMO THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RGNX REGENXBIO INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
KO COCA-COLA COMPANY
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
VRNA VERONA PHARMA ADS
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
AVRO AVROBIO
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
MGTA MAGENTA THERAPEUTICS
AX AXOS FINANCIAL INC.
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
ISEE IVERIC BIO
IMUX IMMUNIC INC
GOSS GOSSAMER BIO
BCEL ATRECA
STOK STOKE THERAPEUTICS
DT DYNATRACE INC.
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
KDNY CHINOOK THERAPEUTICS
PASG INC.
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
FRLN ADICET BIO INC
ITOS FREELINE THERAPEUTICS HOLDINGS ADS
INZY ITEOS THERAPEUTICS
ZNTL INOZYME PHARMA
BEAM ZENTALIS PHARMACEUTICALS
GBIO BEAM THERAPEUTICS
PRAX GENERATION BIO
COGT PRAXIS PRECISION MEDICINES
TVTX COGENT BIOSCIENCES INC
KNTE TRAVERE THERAPEUTICS INC
VRDN KINNATE BIOPHARMA
VOR VIRIDIAN THERAPEUTICS INC
NUVB VOR BIOPHARMA
DAWN NUVATION BIO INC (A)
CYT DAY ONE BIOPHARMACEUTICALS INC
ELEV CYTEIR THERAPEUTICS
FHTX INC
OMGA ELEVATION ONCOLOGY
SBTX FOGHORN THERAPEUTICS
TNGX OMEGA THERAPEUTICS
LBPH SILVERBACK THERAPEUTICS
THRX TANGO THERAPEUTICS
VERA INC
TSVT LONGBOARD PHARMACEUTICALS
DSGN THESEUS PHARMACEUTICALS
ATXS INC.
AVTE VERA THERAPEUTICS INC
CMPX 2SEVENTY BIO INC
GMTX DESIGN THERAPEUTICS INC
RLYB ASTRIA THERAPEUTICS INC
JANX AEROVATE THERAPEUTICS INC
KRTX COMPASS THERAPEUTICS
FUSN GEMINI THERAPEUTICS INC
VIGL RALLYBIO CORP
MLTX JANUX THERAPEUTICS INC
RANI KARUNA THERAPEUTICS INC
EWTX FUSION PHARMACEUTICALS INC
NUVL VIGIL NEUROSCIENCE INC
OCS MOONLAKE IMMUNOTHERAPEUTICS
RANI ZIM SHOPPING CENTERS LTD
EDGEWISE THERAPEUTICS INC
NUVALENT INC
OCULIS HOLDING AG
David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
 PRESS RELEASE

Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreeme...

Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus’ portfolio of next-generation antibody complement therapeutics Combined company is expected to have approximately $180 million of cash or cash equivalents at close, including approximately $70 million from a concurrent private financing by Dianthus’ new and existing investors, which is expected to provide funding into mid-2026 Cash expected to fund lead program DNTH103 through multiple clinical data catalysts including ...

Thomas J. Schiessle
  • Thomas J. Schiessle

Erfolgreiches FY 22 - MGTA-117 im Februar 2023 gestoppt – ATAC®-Techno...

Das Leitprojekt HDP-101 zeigte bisher Sicherheit und gute Verträglichkeit; umso mehr überraschte der ATAC-Wirkstoff MGTA-117 vom Partner Magenta mit einer dosislimitierenden Toxizität in seiner dritten Patientenkohorte (CN vom 25.01.23). Die klinische Ph 1/2-Studie bei Magenta wurde ausgesetzt. Interessanterweise wurden alle Projekte dort eingestellt, auch diejenigen ohne Bezug zu ATAC®. Magenta prüft nun „alle strategischen Optionen“. Nach eigener Aussage des Heidelberg Pharma Managements lieg...

 PRESS RELEASE

Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan

Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”). The Rights Plan will give the Board sufficient time to conduct its previously announced comprehensive review of strategic alternatives focused on maximizing shareholder value. The Rights Plan has been adopted in order to protect the best interests of the C...

David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch